Editorial Commentary
Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer
Abstract
Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid malignancies, but responses are heterogeneous with benefit generally limited to only a fraction of patients.
